Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ananda PharmaAQSE:ANA +14.58% EBITDA Margin % is -31,080.00% as of Jul. 2025. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Ananda Pharma ranks worse than 99.69% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ananda Pharma's EBITDA for the
six
months ended in Jul. 2025 was £-1.55 Mil. Ananda Pharma's Revenue for the
six
months ended in Jul. 2025 was £0.01 Mil. Therefore, Ananda Pharma's EBITDA margin for the quarter that ended in Jul. 2025 was -31,080.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ananda Pharma EBITDA Margin % Related Terms
Ananda Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ananda Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSE:ANA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ananda Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ananda Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ananda Pharma (AQSE:ANA) has a EBITDA Margin % of -31,080.00% as of Jul. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ananda Pharma and its competitors. According to the industry distribution chart, Ananda Pharma ranks #956 out of 959 companies in the Drug Manufacturers industry, placing it in the top 99.7%.
Is Ananda Pharma's EBITDA Margin % too high?
Ananda Pharma's current EBITDA Margin % is -31,080.00%. Based on the distribution chart, Ananda Pharma ranks #956 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ananda Pharma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ananda Pharma ranks #956 out of 959 companies for EBITDA Margin %. This places Ananda Pharma in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ananda Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ananda Pharma's current EBITDA Margin % is -31,080.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (AQSE:ANA) has a current EBITDA Margin % of -31,080.00%. The current EBITDA Margin % is -31,080.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ananda Pharma (AQSE:ANA), the current EBITDA Margin % is -31,080.00% as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:ANA has been successfully added to your 
